Valeo Pharma Inc. operates as a pharmaceutical company focused on licensing, acquiring, and commercializing drugs. The company provides commercialized pharmaceutical products in Canada, with a focus on respiratory/allergy, ophthalmology, and specialty therapeutic areas. It licenses and acquires Canadian rights to commercial-stage and proprietary drugs, managing registration and commercialization t...
Valeo Pharma reported revenue of 53.91 million CAD for fiscal year 2023, up 94.3% from fiscal year 2022, and net income of -27.81 million CAD. In Q3 2024 (the quarter ended July 31, 2024) revenue was 12.60 million CAD, down 10.5% from a year before.
Figures from company filings; latest fiscal year ended October 31, 2023.
No profile data available.